Australia · Delayed Price · Currency is AUD Orthocell Company Description
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally.
It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair.
The company also develops Collagen Medical Device platform products for nerve, tendon, and ligament repair; and Tendon Cell Therapy for rotator cuff and lateral epicondyle indications.
Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
Contact Details
Address: Building 191 Murdoch, 6150 Australia | |
| Phone | 61 8 9360 2888 |
| Website | orthocell.com |
Stock Details
| Ticker Symbol | OCC |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000OCC6 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Paul Frederick Anderson | Chief Executive Officer, MD and Executive Director |
| Jim Piper | Chief Financial Officer |
| Alex McHenry | Chief Operating Officer |
| Prof. Ming Hao Zheng | Chief Scientific Officer and Member of Medical and Scientific Advisory Board |
| John Walker | Vice President of Sales |
| Kevin Leach | Head of Marketing |
| Tony Macintyre | Chief Technical Operations Officer |
| Adam Wood | Chief Commercial Officer |
| Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. | Company Secretary |